In responders, treatment with FMT was associated with a favorable immune change in tumor microenvironment, including upregulation of the IFN-γ-mediated signaling pathway, MHC-II protein expression, dendritic cell differentiation, TH1 cell response, and an increased infiltration of CD8+ T cells (150). The gene discussed is CD8A; the disease is neoplasm.